NCT01709370

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

Phase II Neoadjuvant Study of Letrozole in Combination With PD0332991 (Oral CDK 4/6 Inhibitor) for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Organisation for Oncology and Translational Research · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II study evaluating the efficacy and safety of the pre-operative use of letrozole plus PD 0332991 (combination therapy)

Conditions

• ER Positive, HER2 Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	Letrozole, PD 0332991

Timeline

• Start date: 2012-02-01
• First posted: 2012-10-18
• Last updated: 2013-12-31

Locations

1 site across 1 country: China